- Oops!Something went wrong.Please try again later.
LOS ANGELES, CA / ACCESSWIRE / October 23, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Fennec Pharmaceuticals Inc. ("Fennec" or "the Company") (NASDAQ:FENC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between February 11, 2020 and August 10, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before November 2, 2020.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com or by email at firstname.lastname@example.org.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Fennec's production facilities for its PEDMARK product candidate failed to maintain good manufacturing practices. This failure was likely to delay the regulatory approval of PEDMARK. Based on this news, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Fennec, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
SOURCE: The Schall Law Firm
View source version on accesswire.com: